mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3.

Shi, Guoli; Ozog, Stosh; Torbett, Bruce E; Compton, Alex A

Shi, Guoli; Ozog, Stosh; Torbett, Bruce E; Compton, Alex A.

Affiliation

Shi G; HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702.
Ozog S; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Torbett BE; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037.
Compton AA; HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702; alex.compton@nih.gov.

Proc Natl Acad Sci U S A ; 115(43): E10069-E10078, 2018 10 23.

Article in En | MEDLINE | ID: mdl-30301809

Subject(s)

Antiviral Agents/pharmacology; Membrane Proteins/metabolism; RNA-Binding Proteins/metabolism; TOR Serine-Threonine Kinases/antagonists & inhibitors; Virus Diseases/drug therapy; Virus Diseases/metabolism; Virus Internalization/drug effects; Cell Line; Cell Line, Tumor; Endosomes/drug effects; Endosomes/metabolism; Endosomes/virology; HEK293 Cells; HeLa Cells; Host-Pathogen Interactions/drug effects; Humans; Protein Transport/drug effects; Sirolimus/pharmacology; Virus Diseases/virology

Key words

IFITM; endosome; fusion; interferon; virus

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Virus Diseases / RNA-Binding Proteins / Virus Internalization / TOR Serine-Threonine Kinases / Membrane Proteins Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google